Akari Therapeutics is a clinical-stage biopharmaceutical company. It develops inhibitors of acute and chronic autoimmune and inflammatory diseases, specifically the complement system, the eicosanoid or leukotriene system, and the bioamine system.
|HQ||New York, US||Map|
|Employees (est.) (Feb 2020)||13|
|Share Price (May 2020)||$2.1||(+5%)|
Market capitalization (26-May-2020)
Closing stock price (26-May-2020)
Akari Therapeutics has 145 Twitter Followers. The number of followers has increased 8.2% month over month and increased 9.4% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Akari Therapeutics founded?
Akari Therapeutics was founded in 2014.
Who are Akari Therapeutics key executives?
Akari Therapeutics's key executives are Ray Prudo, Clive Richardson and Wynne Weston-Davies.
How many employees does Akari Therapeutics have?
Akari Therapeutics has 13 employees.
Who are Akari Therapeutics competitors?
Competitors of Akari Therapeutics include SmartZyme, Centrexion and Servier.
Where is Akari Therapeutics headquarters?
Akari Therapeutics headquarters is located at 24 W 40th St, New York.
Where are Akari Therapeutics offices?
Akari Therapeutics has offices in New York and London.
How many offices does Akari Therapeutics have?
Akari Therapeutics has 4 offices.
Receive alerts for 300+ data fields across thousands of companies